Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | OCI-LY3 is a human diffuse large B-cell lymphoma (DLBCL) cell line belonging to the activated B-cell-like (ABC) subtype. Established in 1983 at the Ontario Cancer Institute, the cell line was derived from the bone marrow of a 52-year-old Caucasian male patient who was experiencing a disease relapse (stage IVB). In suspension culture, these cells grow as single, round cells or in small clusters. OCI-LY3 has become a reference model for studying persistent B-cell receptor (BCR) signaling in ABC-DLBCL. The cell line exhibits an immunophenotype characteristic of mature B cells, expressing surface IgG lambda and cytoplasmic IgM lambda; it also expresses CD19, CD20, CD37, CD38, CD80, and HLA-DR, while lacking expression of CD3, CD10, CD34, and CD138. OCI-LY3 is widely used in research concerning the dysregulation of the NF-κB pathway in ABC-DLBCL, responses to BTK and BCL2 inhibitors, and mechanisms of chemotherapy resistance. Furthermore, it serves as a key cell line in large-scale pharmacogenomic screens and CRISPR-based functional genomic screens. |
| Tissue | Bone marrow (in situ, at relapse) |
| Disease | Diffuse Large B-Cell Lymphoma (DLBCL); Activated B-Cell-like (ABC) subtype |
| Morphology | Round cells, single or in small clusters |
| Gender | Male |
| Age | 52 years |
| Ethnicity | Caucasian |
| Product Format | Frozen |
| Growth Mode | Suspension |
| Biosafety Level | 1 (Biosafety classification is based on U.S. Public Health Service Guidelines) |
| Applications | 1. Study of chronic active B-cell-receptor signaling and NF-κB pathway dysregulation in ABC-DLBCL 2. Functional characterization of MYD88 and CARD11 oncogenic mutations in lymphoma 3. Evaluation of BTK inhibitors, BCL2 inhibitors and other targeted therapies in ABC-DLBCL 4. Investigation of chemoresistance mechanisms, including venetoclax and proteasome inhibitors 5. Large-scale anticancer drug sensitivity screening (CCLE, DepMap, LL-100) 6. In vivo xenograft efficacy studies in immunodeficient mice |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Tumorigenic | Yes, forms tumors in immunodeficient (nude) mice following subcutaneous inoculation |
| Karyotype | Human hyper-triploid; modal number 72–77 with multiple der(1), der(4), der(6), der(7), der(14) and der(19) rearrangements |
| Expression Markers | Positive for CD19, CD20, CD37, CD38, CD80, HLA-DR, cyCD79a, surface IgGλ and cytoplasmic IgMλ. Negative for CD3, CD10, CD13, CD34 and CD138 |
| Mycoplasma Test | Negative (PCR) |
| Viral Status | Negative for HBV, HCV, HIV-1, HIV-2 and MLV. EBV reported negative in published literature |
| Culture Conditions and Handling | |
| Subculturing | 1. Collect the cell suspension into a centrifuge tube and centrifuge at approximately 200 × g for 5 minutes. 2. Carefully discard the supernatant. 3. Resuspend the cell pellet in fresh complete growth medium and gently pipette to break up any cell aggregates. 4. Count the cells and adjust to the recommended seeding density with fresh medium. 5. Aliquot the cell suspension into new culture vessels. |
| Medium Renewal | 2 to 3 times per week |
| Subcultivation Ratio | Maintain cells at 0.1-0.8 × 10⁶ cells/mL; split at a ratio of 1:3 to 1:5 every 2 to 3 days. |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | Use a defined serum-free cryopreservation medium, or 70% complete growth medium + 20% FBS + 10% DMSO |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RR0638 | Luciferase Reporter Cell Line - OCI-LY3 | Inquiry |
| CSC-RO01631 | OVAL Stable Cell Line - OCI-LY3 | Inquiry |
| CSC-RO01884 | GFP/OVAL Stable Cell Line - OCI-LY3 | Inquiry |
| CSC-RO02137 | Luc/OVAL Stable Cell Line - OCI-LY3 | Inquiry |
| CSC-RO02390 | GFP/Luc/OVAL Stable Cell Line - OCI-LY3 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.